|
Market Closed -
Nasdaq
21:00:00 14/08/2025 BST
|
5-day change | 1st Jan Change | ||
| 100.99 USD | +0.01% |
|
-.--% | - |
| Market Cap | 3.32B 2.86B 2.69B 2.45B 4.58B 315B 4.6B 31.83B 12.32B 161B 12.47B 12.2B 512B | P/E 2023 |
-317x | P/E 2024 | 69.3x |
|---|---|---|---|---|---|
| Enterprise Value | 3.48B 2.99B 2.81B 2.57B 4.79B 330B 4.81B 33.33B 12.89B 168B 13.06B 12.77B 536B | EV / Sales 2023 |
1.55x | EV / Sales 2024 | 1.33x |
| Free-Float |
-
| Yield 2023 * |
-
| Yield 2024 | - |
| 30/09/25 | A CEO's Playbook For Navigating Crisis And Building Trust (Video) | AQ |
| 29/07/25 | Amedisys: Q2 Earnings Snapshot | AQ |
| 29/07/25 | Amedisys : Second Quarter 2025 Earnings Release Supplemental Slides | PU |
| 29/07/25 | Amedisys Reports Second Quarter 2025 Financial Results | AQ |
| 23/04/25 | Amedisys: Q1 Earnings Snapshot | AQ |
| 1 day | +0.01% |
| 3 years | 82.15 |  | 101.02 |
| 5 years | 69.36 | | 188.88 |
| 10 years | 34.58 | | 325.12 |
| Manager | Title | Age | Since |
|---|---|---|---|
Scott Ginn
DFI | Director of Finance/CFO | 57 | 05/10/2017 |
Keith Blanchard
CTO | Chief Tech/Sci/R&D Officer | - | - |
Denise Bohnert
CMP | Compliance Officer | 48 | 31/12/2016 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 14/08/25 | Issuer sale | Director | 9,818 | 0.0300% | ||
| 14/08/25 | Issuer sale | Director | 9,818 | 0.0300% | ||
| 14/08/25 | Issuer sale | Chief Executive Officer | 520,347 | 1.5886% |
| 2023 | 2024 | |
|---|---|---|
| Net sales | 2.24B 1.92B 1.81B 1.65B 3.08B 212B 3.1B 21.43B 8.29B 108B 8.4B 8.21B 345B | 2.35B 2.02B 1.9B 1.73B 3.24B 223B 3.25B 22.51B 8.71B 114B 8.82B 8.63B 362B |
| Net income | -9.75M -8.38M -7.88M -7.2M -13.43M -924M -13.5M -93.42M -36.14M -472M -36.6M -35.8M -1.5B | 43.23M 37.17M 34.97M 31.91M 59.55M 4.1B 59.86M 414M 160M 2.09B 162M 159M 6.67B |
| Net Debt | 361M 310M 292M 266M 497M 34.2B 500M 3.46B 1.34B 17.48B 1.35B 1.33B 55.63B | 156M 134M 126M 115M 215M 14.79B 216M 1.5B 579M 7.56B 586M 573M 24.06B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- AMED Stock
Select your edition
All financial news and data tailored to specific country editions
